Mathew S. Maurer, MD
- Professor of Medicine at CUMC
Mathew S. Maurer, MD, is medical director of The HCM Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. A general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation, he has received grants from the National Institute on Aging to study cardiovascular changes in older patients and specializes in the care of patients with heart failure and a preserved ejection fraction, including patients with HCM. Dr. Maurer is an associate professor of Medicine at Columbia University, College of Physicians and Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYork-Presbyterian Hospital. Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork-Presbyterian/Columbia.
Dr. Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship. He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He completed training in internal medicine and cardiology at NewYork-Presbyterian Hospital and was chief medical resident.
I am interested in understanding how age related changes in cardiovascular structure and function contribute to cardiovascular disorders that disproportionately afflict the elderly.
Languages Spoken
- Spanish
Education & Training
- Mount Sinai School of Medicine CUNY
- Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
Links
NIH Grants
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PATISIRAN WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (P&S Industry Clinical Trial)
Nov 7 2019 - Nov 7 2024
SCAN-MP (SCREENING FOR CARDIAC AMYLOIDOSISWITH NUCLEAR IMAGING IN MINORITY POPULATIONS) (Federal Gov)
May 1 2019 - Feb 29 2024
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE MAVACAMTEN (MYK-461) IN ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY. (P&S Industry Clinical Trial)
Nov 15 2018 - Nov 15 2023
AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH SYMPTOMATIC TRANSTHYRETIN CARDIOMYOPATHY WHO HAVE COMPLETED THE PHASE II STUDY AG10-201 (P&S Industry Clinical Trial)
Jul 25 2018 - Jul 25 2023
A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF INTRAVENOUS PRX004 IN SUBJEXTS WITH AMYLOID TRANSTHYRETIN (ATTR) AMYLOIDOSIS (P&S Industry Clinical Trial)
May 12 2018 - May 12 2023
A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG10 IN PATIENTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (P&S Industry Clinical Trial)
Apr 24 2018 - Apr 24 2023
QUALITATIVE AND QUANTITATIVE DATA ANALYSIS FOR ATTR STUDY (P&S Industry Clinical Trial)
Jun 26 2017 - Jun 26 2022
EFFECTS OF DAPAGLIFLOZIN ON BIOMARKERS, SYMPTOMS AND FUNCTIONAL STATUS IN PATIENTS WITH TYPE 2 DIABETES OR PRE-DIABETES, AND PRESERVED EJECTION FRACTION HEART FAILURE (PRESERVED-HF TRIAL) (P&S Industry Clinical Trial)
May 22 2017 - May 22 2022
PROBING THE BIOCHEMICAL MECHANISMS OF AMYLOID DISEASE (Federal Gov)
Sep 16 2016 - Jun 30 2021
MIDCAREER MENTORING AWARD FOR PATIENT ORIENTED RESEARCH IN GERIATRIC CARDIOLOGY (Federal Gov)
Sep 30 2010 - Apr 30 2021
ANALYSIS OF LUMBAR SPINE STENOSIS SPECIMENTS FOR EARLY IDENTIFICATION OF TTR CARDIAC AMYLOIDOSIS (Federal Gov)
Sep 1 2018 - May 31 2020
NEOD001-CL002 SAFETY MONITORING COMMITTEE (P&S Industry Clinical Trial)
Mar 2 2015 - Mar 2 2020
SA SCIENTIFICADVIS-MAURERSOW2 (P&S Industry Clinical Trial)
Mar 2 2015 - Mar 2 2020
A PHASE 2, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG- TERM SAFETY, CLINICAL ACTIVITY, AND PHARMACOKINETICS OF ALN- TTRSC IN PATIENTS WITH TRANSTHRETIN (TTR) CARDIAC AMYLOIDOSIS WHO HAVE PREVIOUSLY RECEIVED ALN- TTRSC (P&S Industry Clinical Trial)
Jan 6 2015 - Jan 6 2020
CARDIAC AMYLOIDOSIS FELLOWSHIP (Private)
Jan 1 2019 - Dec 31 2019
DISCOVERING AND APPLYING KNOWLEDGE IN CLINICAL DATABASES (Federal Gov)
Sep 30 2013 - Sep 29 2019
SERVICE AGREEMENT- ISIS PHARMACEUTICALS, INC. (P&S Industry Clinical Trial)
Sep 25 2014 - Sep 25 2019
PFIZER STEERING COMMITTEE CONSULTING AGREEMENT (P&S Industry Clinical Trial)
Jul 8 2014 - Jul 8 2019
A PHASE 2, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) CARDIAC AMYLOIDOSIS (P&S Industry Clinical Trial)
Feb 21 2014 - Feb 21 2019
A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (P&S Industry Clinical Trial)
Jan 28 2014 - Jan 28 2019
RETROSCEPTIVE CLINICAL DATA COLLECTION (P&S Industry Clinical Trial)
Sep 4 2013 - Sep 4 2018
FOLDRX -- FX-R-001 (P&S Industry Clinical Trial)
Dec 4 2007 - Jun 30 2018
SERIAL TC-99M PYROPHOSPHATE SCANNING FOR ATTR CARDAIC AMYLOIDOSIS (P&S Industry Clinical Trial)
Mar 15 2013 - Mar 15 2018
CAN VENTRICULAR ASSIST DEVICES REVERSE THE FRAILTY PHENOTYPE (Federal Gov)
Sep 1 2014 - Apr 30 2017
DASH-SRD POST ACUTE DECOMPENSATED HEART FAILURE HOSPITALIZATION (Federal Gov)
Sep 1 2014 - Apr 30 2017
PHOSPHODIESTERASE TYPE 5 INHIBITION WITH TADALAFIL CHANGES OUTCOMES IN HEART FAILURE (Federal Gov)
May 1 2013 - Jan 31 2017
WS1906665 (P&S Industry Clinical Trial)
Jan 26 2012 - Jan 26 2017
TECHNETIUM PYROPHOSPHATE CARDIAC IMAGING TO DETERMINE IF TRANSTHYRETIN CARDIAC AMYLOIDOSIS EXPLAINS PARADOXICAL LOW-FLOW SEVERE AORTIC STENOSIS (Private)
Jul 1 2015 - Jun 30 2016
CHARACTERIZING THE FUNCTIONAL SIGNIFICANCE OF THE HIGHLY PROGNOSTIC FGD3-SUSD3 METAGENE IN BREAST CANCER (Private)
Jun 1 2014 - May 31 2016
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PARALLEL GROUP,ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LC (P&S Industry Clinical Trial)
Feb 16 2010 - Feb 16 2015
OPEN-LABEL SAFETY AND EFFICACY OF FX-1006A IN PATIENTS WITH V122I OR WILD-TYPE TRANTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY (P&S Industry Clinical Trial)
Sep 14 2009 - Sep 14 2014
TREATING TO EUVOLEMIA BY CLINICAL ASSESSMENT AND MEASURED BLOOD VOLUME IN HEART FAILURE (P&S Industry Clinical Trial)
Aug 24 2009 - Aug 24 2014
PHYSICAL ACTIVITY, DEPRESSION, AND POST-ACS (Federal Gov)
Sep 1 2009 - Jun 30 2014
PILOT PROJECT IN PATIENTS PRE AND POSTOP AORTIC VALVE SURGER (Federal Gov)
Sep 15 2011 - Jul 2 2013
RISK STRATIFICATION IN OLDER PERSONS WITH ACUTE MYOCARDIAL INFARCTION: SILVER-AM (Federal Gov)
Aug 18 2012 - May 31 2013
FOLDRX --FX R 001 S1 (P&S Industry Clinical Trial)
May 16 2008 - Jun 30 2012
PATHOPHYSIOLOGY OF HEART FAILURE WITH A NORMAL EJECTION FRAC TION IN THE ELDERLY (Federal Gov)
Apr 1 2007 - Mar 31 2012
RESYNCHRONIZATION REVERSES REMODELING IN SYSTOLIC LEFT VENTRICULAR DYSFUNCTION (REVERSE) (P&S Industry Clinical Trial)
Feb 3 2006 - Dec 31 2011